First patient IV dosed in VAXINIA Phase 1 clinical trial
Filed with ASX · · 2 pages · English
Story so far
Earlier from Imugene
- OGTR grants VAXINIA DIR licence allowing trial expansion
- Prospectus for the issue of institutional placement options
- Imugene announces a$80 million institutional placement
- Imugene doses first patient in nextHERIZON Phase 2 trial
- Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA
Later from Imugene
- Preclinical trial of ALA iNKT therapy and IMU onCARlytics
- First patient dosed in VAXINIA intratumoral cohort 2
- Europe Patent granted for iNKT Cell Therapy Platform
- Imugene onCARlytics with blinatumomab SITC presentation
- Dose escalates In Phase I Clinical Trial of New Oncolytic Vi
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene